Items Tagged ‘BRCA1’

October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


July 13th, 2016

Niraparib Improves Progression-Free Survival in Ovarian Cancer

By

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer, and is the fifth most common cause of cancer-related deaths among women. Since there are no generalized […]

View full entry

Tags: BRCA1, BRCA2, News, niraparib, NOVA trial, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer


March 8th, 2016

Age of Breast Cancer Diagnosis Associated with Risk of Second Breast Cancer in BRCA1/2 Mutation Carriers

By

Among women with the BRCA1 and/or BRCA2 mutations, the age of diagnosis of breast cancer is strongly associated with their risk of developing a second breast cancer in their contralateral (opposite) breast. These results were recently published as a rapid communication in the Journal of Clinical Oncology. Individuals who have certain mutations referred to as […]

View full entry

Tags: age, BRCA1, BRCA2, Breast Cancer, contralateral, News, risk